{"count": 8, "results": [{"_id": "24459612", "pmid": 24459612, "pmcid": "PMC3871420", "title": "A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy", "journal": "PLoS Curr", "authors": ["Allen HD", "Flanigan KM", "Thrush PT", "Dvorchik I", "Yin H", "Canter C", "Connolly AM", "Parrish M", "McDonald CM", "Braunlin E", "Colan SD", "Day J", "Darras B", "Mendell JR"], "date": "2013-12-12T00:00:00Z", "doi": "10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865", "meta_date_publication": "2013 Dec 12", "meta_volume": "5", "meta_issue": "", "meta_pages": "", "score": 50072.023, "text_hl": "We hypothesized that @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ have equal efficacy in the treatment of @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@DMD CM@@@. ", "citations": {"NLM": "Allen HD, Flanigan KM, Thrush PT, Dvorchik I, Yin H, Canter C, Connolly AM, Parrish M, McDonald CM, Braunlin E, Colan SD, Day J, Darras B, Mendell JR. A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy PLoS Curr. 2013 Dec 12;5():. PMID: 24459612", "BibTeX": "@article{24459612, title={A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy}, author={Allen HD and Flanigan KM and Thrush PT and Dvorchik I and Yin H and Canter C and Connolly AM and Parrish M and McDonald CM and Braunlin E and Colan SD and Day J and Darras B and Mendell JR}, journal={PLoS Curr}, volume={5}}"}}, {"_id": "29971804", "pmid": 29971804, "title": "An evidence-based systematic review of the off-label uses of lisinopril.", "journal": "Br J Clin Pharmacol", "authors": ["Sadat-Ebrahimi SR", "Parnianfard N", "Vahed N", "Babaei H", "Ghojazadeh M", "Tang S", "Azarpazhooh A"], "date": "2018-11-01T00:00:00Z", "doi": "10.1111/bcp.13705", "meta_date_publication": "2018 Nov", "meta_volume": "84", "meta_issue": "11", "meta_pages": "2502-2521", "score": 50071.484, "text_hl": "An evidence-based systematic review of the off-label uses of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@.", "citations": {"NLM": "Sadat-Ebrahimi SR, Parnianfard N, Vahed N, Babaei H, Ghojazadeh M, Tang S, Azarpazhooh A. An evidence-based systematic review of the off-label uses of lisinopril. Br J Clin Pharmacol. 2018 Nov;84(11):2502-2521. PMID: 29971804", "BibTeX": "@article{29971804, title={An evidence-based systematic review of the off-label uses of lisinopril.}, author={Sadat-Ebrahimi SR and Parnianfard N and Vahed N and Babaei H and Ghojazadeh M and Tang S and Azarpazhooh A}, journal={Br J Clin Pharmacol}, volume={84}, number={11}, pages={2502-2521}}"}}, {"_id": "21768542", "pmid": 21768542, "title": "Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.", "journal": "Circulation", "authors": ["Rafael-Fortney JA", "Chimanji NS", "Schill KE", "Martin CD", "Murray JD", "Ganguly R", "Stangland JE", "Tran T", "Xu Y", "Canan BD", "Mays TA", "Delfín DA", "Janssen PM", "Raman SV"], "date": "2011-08-02T00:00:00Z", "doi": "10.1161/CIRCULATIONAHA.111.031716", "meta_date_publication": "2011 Aug 2", "meta_volume": "124", "meta_issue": "5", "meta_pages": "582-8", "score": 50071.383, "text_hl": "Early treatment with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ preserves cardiac and skeletal muscle in @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@Duchenne muscular dystrophy@@@ @SPECIES_10090 @@@mice@@@.", "citations": {"NLM": "Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfín DA, Janssen PM, Raman SV. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation. 2011 Aug 2;124(5):582-8. PMID: 21768542", "BibTeX": "@article{21768542, title={Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.}, author={Rafael-Fortney JA and Chimanji NS and Schill KE and Martin CD and Murray JD and Ganguly R and Stangland JE and Tran T and Xu Y and Canan BD and Mays TA and Delfín DA and Janssen PM and Raman SV}, journal={Circulation}, volume={124}, number={5}, pages={582-8}}"}}, {"_id": "25821645", "pmid": 25821645, "pmcid": "PMC4358986", "title": "Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy", "journal": "PLoS Curr", "authors": ["PLOS Currents"], "date": "2015-03-06T00:00:00Z", "doi": "10.1371/currents.md.995441cf82fd58a29c6e4fdd5cd36b89", "meta_date_publication": "2015 Mar 6", "meta_volume": "7", "meta_issue": "", "meta_pages": "", "score": 50068.375, "text_hl": "Correction: A Randomized, Double-Blind Trial of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ and @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@Losartan@@@ for the Treatment of @DISEASE_Cardiomyopathies @DISEASE_MESH:D009202 @@@Cardiomyopathy@@@ in @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@Duchenne Muscular Dystrophy@@@", "citations": {"NLM": "PLOS Currents. Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy PLoS Curr. 2015 Mar 6;7():. PMID: 25821645", "BibTeX": "@article{25821645, title={Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy}, author={PLOS Currents}, journal={PLoS Curr}, volume={7}}"}}, {"_id": "22392872", "pmid": 22392872, "title": "Letter by Fayssoil regarding article, \"Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice\".", "journal": "Circulation", "authors": ["Fayssoil A"], "date": "2012-03-06T00:00:00Z", "doi": "10.1161/CIRCULATIONAHA.111.061093", "meta_date_publication": "2012 Mar 6", "meta_volume": "125", "meta_issue": "9", "meta_pages": "e429", "score": 50067.14, "text_hl": "Letter by Fayssoil regarding article, \"Early treatment with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ preserves cardiac and skeletal muscle in @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@Duchenne muscular dystrophy@@@ @SPECIES_10090 @@@mice@@@\".", "citations": {"NLM": "Fayssoil A. Letter by Fayssoil regarding article, \"Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice\". Circulation. 2012 Mar 6;125(9):e429. PMID: 22392872", "BibTeX": "@article{22392872, title={Letter by Fayssoil regarding article, \"Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice\".}, author={Fayssoil A}, journal={Circulation}, volume={125}, number={9}, pages={e429}}"}}, {"_id": "27881412", "pmid": 27881412, "title": "Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.", "journal": "Am J Physiol Cell Physiol", "authors": ["Chadwick JA", "Bhattacharya S", "Lowe J", "Weisleder N", "Rafael-Fortney JA"], "date": "2017-02-01T00:00:00Z", "doi": "10.1152/ajpcell.00269.2016", "meta_date_publication": "2017 Feb 1", "meta_volume": "312", "meta_issue": "2", "meta_pages": "C155-C168", "score": 50064.05, "text_hl": "Combined treatment with the ACEi @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and the nonspecific MR antagonist @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ surprisingly improves skeletal muscle, in addition to heart function and pathology in a @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@Duchenne muscular dystrophy@@@ (@<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@DMD@@@) @SPECIES_10090 @@@mouse@@@ model. ", "citations": {"NLM": "Chadwick JA, Bhattacharya S, Lowe J, Weisleder N, Rafael-Fortney JA. Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles. Am J Physiol Cell Physiol. 2017 Feb 1;312(2):C155-C168. PMID: 27881412", "BibTeX": "@article{27881412, title={Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.}, author={Chadwick JA and Bhattacharya S and Lowe J and Weisleder N and Rafael-Fortney JA}, journal={Am J Physiol Cell Physiol}, volume={312}, number={2}, pages={C155-C168}}"}}, {"_id": "26178166", "pmid": 26178166, "title": "Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.", "journal": "FASEB J", "authors": ["Chadwick JA", "Hauck JS", "Lowe J", "Shaw JJ", "Guttridge DC", "Gomez-Sanchez CE", "Gomez-Sanchez EP", "Rafael-Fortney JA"], "date": "2015-11-01T00:00:00Z", "doi": "10.1096/fj.15-276782", "meta_date_publication": "2015 Nov", "meta_volume": "29", "meta_issue": "11", "meta_pages": "4544-54", "score": 50062.273, "text_hl": "Early treatment with @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@ drugs @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ improves skeletal muscle pathology in @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@Duchenne muscular dystrophy@@@ (@<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@DMD@@@) @SPECIES_10090 @@@mouse@@@ models. ", "citations": {"NLM": "Chadwick JA, Hauck JS, Lowe J, Shaw JJ, Guttridge DC, Gomez-Sanchez CE, Gomez-Sanchez EP, Rafael-Fortney JA. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 2015 Nov;29(11):4544-54. PMID: 26178166", "BibTeX": "@article{26178166, title={Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.}, author={Chadwick JA and Hauck JS and Lowe J and Shaw JJ and Guttridge DC and Gomez-Sanchez CE and Gomez-Sanchez EP and Rafael-Fortney JA}, journal={FASEB J}, volume={29}, number={11}, pages={4544-54}}"}}, {"_id": "28432191", "pmid": 28432191, "title": "Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.", "journal": "Physiol Genomics", "authors": ["Chadwick JA", "Hauck JS", "Gomez-Sanchez CE", "Gomez-Sanchez EP", "Rafael-Fortney JA"], "date": "2017-06-01T00:00:00Z", "doi": "10.1152/physiolgenomics.00128.2016", "meta_date_publication": "2017 Jun 1", "meta_volume": "49", "meta_issue": "6", "meta_pages": "277-286", "score": 50043.3, "text_hl": "We recently identified mineralocorticoid receptors (MR) in skeletal muscles after finding that combined treatment with the @GENE_ACE @GENE_11421 @@@angiotensin-converting enzyme@@@ inhibitor @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and @GENE_NR3C2 @GENE_110784 @@@MR@@@ antagonist @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ was therapeutic in @<m>DISEASE_Muscular_Dystrophy_Duchenne</m> @DISEASE_MESH:D020388 @@@Duchenne muscular dystrophy@@@ @SPECIES_10090 @@@mouse@@@ models. ", "citations": {"NLM": "Chadwick JA, Hauck JS, Gomez-Sanchez CE, Gomez-Sanchez EP, Rafael-Fortney JA. Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle. Physiol Genomics. 2017 Jun 1;49(6):277-286. PMID: 28432191", "BibTeX": "@article{28432191, title={Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.}, author={Chadwick JA and Hauck JS and Gomez-Sanchez CE and Gomez-Sanchez EP and Rafael-Fortney JA}, journal={Physiol Genomics}, volume={49}, number={6}, pages={277-286}}"}}]}